Keywords: cell, therapeutics, suffers, lisofylline, trial, data, cuts

Cell Therapeutics suffers on lisofylline trial data, cuts development

Article | 14 October 1999

Cell Therapeutics Inc's investigational compound lisofylline has failedto meet its primary endpoint, a reduction in the incidence of serious neutropenia-associated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Johnson & Johnson

Go to company listing

Related Drugs

Paclitaxel

Taxol

Etoposide

VePesid

Go to drug listing